Fundraising FoxCatalys Pacific — Full Portfolio
11 tracked investments · listed companies and verified rows first
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.
BiotechHealthtechRadnor, US
Eric Warren(Chief Commercial Officer)inAlex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)
BoardOlivier Litzka(Director)in
Board seatTakeshi TakahashiBrian Taylor Slingsby· per SEC Form D
Co-investorsAndera PartnersHBM Healthcare InvestmentsHBM PartnersSamsara BioCapitalSR One Capital ManagementYsios Capital+3 more
Arialys Therapeutics develops precision medicines designed to block pathogenic autoantibodies that target brain receptors such as the NMDA receptor, aiming to treat neuropsychiatric disorders driven by autoimmune disease.
BiotechHealthtechLa Jolla, US
Peter Flynn, Ph.D.(Executive Officer, Director)
BoardJay Lichter, Ph.D.(Director)Brian Slingsby, M.D., Ph.D., M.P.H.(Director)Ed Hurwitz(Director)inAshish Xavier, Ph.D.(Director)Tighe Reardon(Executive Officer)
Co-investorsAvalon BioVenturesMPM BioImpact
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid.
BiotechHealthtechMedical DevicesSan Diego, US
James Mackay(President & Chief Executive Officer)inNihar Bhakta(Chief Medical Officer)inAshwin Ram(Chief Operating Officer)inDeAnne Reid(Chief Administrative Officer)in
Co-investorsNovo HoldingsAN Venture PartnersFrazier Life SciencesLightstone VenturesLongwood Fund
A company with expertise in developing pharmaceutical products through clinical trial phases (IND to NDA/BLA) and launching them for patients in Japan and Asia.
BiotechDigital HealthMedical DevicesTokyo, JP
Co-investorsDBJ CapitalNippon Venture Capital
XOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding.
BiotechFintech
Co-investorsFrazier Life SciencesLightspeed Venture PartnersRA CapitalSamsara BioCapitalFrazier Healthcare Partners
Pathalys Pharma is a biotechnology company developing and improving therapeutic treatments for patients with chronic kidney disease.
BiotechHealthtechResearch Triangle Park, US
BT Slingsby(Co-Founder & Executive Chairman)in
Co-investorsAbingworthOrbiMedSamsara BioCapitalKB Investment
Phathom Pharmaceuticals is a pharmaceutical company that develops and markets prescription treatments, including VOQUEZNA (vonoprazan) for gastrointestinal conditions, in the U.S. market.
BiotechHealthtech
Mr. Basta(CEO)
Co-investorsFrazier Life SciencesNew Enterprise Associates (NEA)Astellas Venture Management LLCMedicxi
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Exalys TherapeuticsAculysKirilysMineralys
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.